News | Intravascular Imaging | September 11, 2015

Infraredx Acquired by Nipro Corp.

Japanese medical company Nipro wants to expand into intravascular imaging solutions, expand vascular portfolio to the United States

Infraredx, NIRS, IVUS

September, 11, 2015 – Japanese medical vendor Nipro Corp. signed a definitive agreement to acquire Infraredx Inc., maker of a combined intravascular ultrasound (IVUS) integrated with near infrared spectroscopy (NIRS) for the detection of lipid-core plaque (LCP) coronary plaque. 

Nipro offers medical products and technologies in a wide range of fields, including artificial organs, circulatory devices, test/diagnostic agents, injection/infusion solutions, pharmaceuticals and medical glass products. The agreement combines Nipro's strong global cardiovascular portfolio and resources along with Infraredx’s industry expertise in NIRS and intravascular ultrasound. The agreement will help introduce Nipro’s cardiovascular product line into the United States. 

The company plans to continue Infraredx’s strategic plans to continue clinical testing of NIRS as an advanced imaging tool required to predict heart attacks and shift from reactive treatment to proactive care of coronary artery disease.

“By teaming up with one of the leading global medical equipment manufacturing companies in the world, Infraredx is able to leverage Nipro’s global network and vast resources to enhance its presence and impact a larger audience locally as well globally,” said Jason Bottiglieri, president and CEO of Infraredx. “We are pleased to combine our strengths to meet the demands of the marketplace and continue to deliver to the medical community cardiovascular imaging systems that hold the potential to revolutionize the management of cardiovascular disease.”

The acquisition, which is subject to certain conditions, is expected to close in October 2015.

For more information: www.infraredx.com

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init